CMMB
Chemomab Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.23
+4.24%Nov 2, 2026, 13:00 UTC
The U.S. Securities and Exchange Commission declared effective the Form S-4 registration statement filed by Chemomab Therapeutics Ltd. and Snowdrift Parent Corp for the proposed business combination with Scipher Medicine.
Source:Aug 19, 2026, 12:26 UTC
Chemomab Therapeutics announced that its planned merger with Scipher Medicine is advancing, with closing expected by year-end.
Source:Aug 19, 2026, 12:26 UTC
Chemomab Therapeutics announced its second quarter 2026 financial results and provided a corporate update.
Source:Jul 8, 2026, 11:35 UTC
Chemomab Therapeutics and Scipher Medicine announced a merger agreement to advance nebokitug in an AI-powered Phase 2 trial for rheumatoid arthritis.